Patent · US Expired

1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives

US7098337B2 · kind B2 · utility

0Cited by

6References

34Claims

0Family size

Assignees

Hoffmann-La Roche Inc. · US
Vernalis Research Limited · GB

Inventors

David Reginald Adams · Wokingham, GB
Jonathan Mark Bentley · Wokingham, GB
Toby Jonathan Blench · Terling, GB
Paul Hebeisen · Basel, CH
Nathaniel Julius Thomas Monck · Abingdon, GB
Hans Richter · Weil am Rhein, DE
Stephan Roever · Inzlingen, DE
Jonathan Richard Anthony Roffey · Wokingham, GB
Sven Taylor · Riedisheim, FR

Key dates

Filing date	Jan 24, 2003
Grant date	Aug 29, 2006
Priority date	—
Expiry date	Jun 20, 2023

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds of formula (I)as well as pharmaceutically acceptable salts, solvates and esters thereof. These compounds can be used to prepare pharmaceutical compositions for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.